Literature DB >> 11895216

Effect of long-term administration of recombinant human growth hormone (rhGH) on plasma erythropoietin (EPO) and haemoglobin levels in anaemic patients with adult GH deficiency.

M Sohmiya1, Y Kato.   

Abstract

OBJECTIVE: We investigated the effect of recombinant human GH (rhGH) on erythropoietin (EPO) and haemoglobin (Hb) concentrations in anaemic patients with adult GH deficiency. PATIENTS AND
DESIGN: rhGH was administrated in 8 patients with adult GH deficiency, three males and five females, aged from 24 to 69 years, mean (+/- SD) of 48.8 +/- 16.4 years, for 1 year by means of continuous subcutaneous infusion (CSI) at a flow rate of 0.036 U/kg/day using a portable syringe pump. Blood samples were obtained in the morning after an overnight fast every week for 1 month, followed by each month before and after the start of rhGH administration.
RESULTS: Mean (+/- SE) plasma GH levels increased from 0.24 +/- 0.09 microg/l to 2.32 +/- 0.23 microg/l 1 week after the start of rhGH administration to maintain a steady state. Plasma IGF-I levels increased from 70.1 +/- 13.8 microg/l to 282.8 +/- 70.6 microg/l 1 week after the start of rhGH administration to maintain the steady state. Plasma EPO levels increased from 25.9 +/- 2.6 IU/l to 37.6 +/- 4.2 IU/l and 34.3 +/- 3.6 IU/l at 1 week and 2 weeks after the start of rhGH administration, respectively, and then decreased gradually to 14-9 +/- 2.1 IU/l at 10 months after the start of rhGH administration. Reticulocyte counts increased from 0.88 +/- 0.06% to 1.49 +/- 0.21% at 1 week. Hb concentrations increased from 103 +/- 5 g/l to 106 +/- 5 g/l at 2 weeks after the start of rhGH administration, and then increased gradually to reach the normal range.
CONCLUSIONS: We conclude that EPO secretion was stimulated in the initial 2 weeks after the start of CSI of rhGH in anaemic patients with adult GH deficiency. Increased Hb concentrations after long-term administration of rhGH might be explained by direct stimulatory effects of rhGH and IGF-I on erythroid cells, which was accompanied by suppressed EPO secretion, in combination with a more generalized indirect impact of rhGH on physical activety. These findings suggest a beneficial effect of rhGH replacement in anaemic patients with adult GH deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11895216     DOI: 10.1046/j.1365-2265.2001.01417.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Hypopituitarism and anemia: effect of replacement therapy with hydrocortisone and/or levothyroxine.

Authors:  H Nishioka; J Haraoka
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

2.  Growth hormone replacement therapy in growth hormone deficient children and adults: Effects on hemochrome.

Authors:  S Bergamaschi; C Giavoli; E Ferrante; A Lania; R Rusconi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

3.  Long-term effects of growth hormone (GH) replacement therapy on hematopoiesis in a large cohort of children with GH deficiency.

Authors:  Andrea Esposito; Donatella Capalbo; Lucia De Martino; Martina Rezzuto; Raffaella Di Mase; Claudio Pignata; Mariacarolina Salerno
Journal:  Endocrine       Date:  2015-10-28       Impact factor: 3.633

Review 4.  Hormones and the bone marrow: panhypopituitarism and pancytopenia in a man with a pituitary adenoma.

Authors:  Dianna Lang; Jennifer S Mead; David B Sykes
Journal:  J Gen Intern Med       Date:  2015-05       Impact factor: 5.128

5.  Correction of hemodialysis anemia is associated with significant increase in serum concentration of IGF-I in patients treated with erythropoietin: a randomized controlled study.

Authors:  Hussein A Sheashaa; Abdalla Khalil; Mohammed M El Aarman; Fagr B El-Shahat; Amal Selim; Soma Sherif Abd El-Gawad
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

6.  Erythropoietin levels in endocrinopathies.

Authors:  E Klein; J Brossaud; B Gatta; J-B Corcuff
Journal:  J Endocrinol Invest       Date:  2011-04-20       Impact factor: 4.256

7.  Prevalence of hematological abnormalities in patients with Sheehan's syndrome: response to replacement of glucocorticoids and thyroxine.

Authors:  Bashir Ahmad Laway; Shahnaz Ahmad Mir; Mir Iftikhar Bashir; Javid Rasool Bhat; Jeelani Samoon; Abdul Hamid Zargar
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

8.  Effects of growth hormone therapeutic supplementation on hematopoietic stem/progenitor cells in children with growth hormone deficiency: focus on proliferation and differentiation capabilities.

Authors:  M P Kawa; I Stecewicz; K Piecyk; E Pius-Sadowska; E Paczkowska; D Rogińska; A Sobuś; K Łuczkowska; E Gawrych; E Petriczko; M Walczak; B Machaliński
Journal:  Endocrine       Date:  2015-04-29       Impact factor: 3.633

Review 9.  Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?

Authors:  Jesús Devesa; Cristina Almengló; Pablo Devesa
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2016-10-12

Review 10.  Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment.

Authors:  Valentina Gasco; Valeria Cambria; Fabio Bioletto; Ezio Ghigo; Silvia Grottoli
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-15       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.